Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry

Sessa argues that psychedelic compounds possess many of the pharmacological and experiential properties that would be desirable in an adjunct to psychotherapy: short-acting profiles amenable to single-session use, low dependence potential, acceptable toxicity at therapeutic doses, capacity to reduce depressive and anxiety symptoms, the facilitation of therapeutic alliance and emotional openness, and, importantly, a reduction in the fear associated with recalling traumatic memories. He contends these combined effects make psychedelics particularly well suited to disorders grounded in anxiety and trauma, such as PTSD and obsessive–compulsive disorder. The author emphasises a dual challenge: the recreational counterculture of the 1960s and 1970s undermined early clinical work by precipitating prohibition and discrediting medical programmes, while the contemporary medical and pharmaceutical establishment has been reluctant to invest in interventions that might reduce long-term reliance on daily pharmacotherapy. He highlights methodological barriers specific to psychedelic psychotherapy research — for example, difficulties in designing convincing placebo controls and double-blinding for intense subjective experiences — and notes that these challenges, together with funding incentives, have constrained large-scale randomized trials. B. discusses the tension between the experiential, often spiritual, elements of psychedelic sessions and the conservative language necessary to obtain funding and scientific legitimacy. He describes a pragmatic strategy adopted by recent researchers: emphasise conservative, mechanistic descriptions to persuade sceptical funders and journals while risking the loss of the transpersonal elements that many users and some practitioners view as therapeutically important. To bridge this gap, he recommends a cautious, phased reintroduction of psychedelics into medical settings, including reworking professional language, considering alternative nomenclature (psycholytic, entheogen, entactogen), and embedding psychedelic approaches in clinical training and university curricula. Economically, B. proposes that psychedelic-assisted psychotherapy could be cost-effective if a small number of focused, drug-assisted sessions produce enduring remission, thereby reducing long-term expenditure on chronic pharmacotherapy and the societal burden of mental illness. He acknowledges substantial social, political, and methodological uncertainties — including persistent negative media framing, regulatory constraints, the need for high-quality evidence, and the difficulty of recapitulating the full naturalistic or cultural contexts of traditional use within clinical settings — and frames his recommendations as pragmatic steps to gain clinical acceptance without repeating the excesses of the 1960s.

In the closing summary, Sessa urges abandoning grandiose aims of social revolution through psychedelics and instead advocates a cautious, conservative professional approach to reintroduce these therapies into mainstream medicine. He contends that clinicians working quietly and rigorously within established methodological and regulatory frameworks have the best chance of securing acceptance for psychedelic-assisted psychotherapy. While he affirms the value of the spiritual and transpersonal aspects of the psychedelic experience, he argues that tempering public rhetoric and emphasising evidence-based practice will allow transpersonal psychotherapy to be integrated into psychiatry "through the back door," thereby effecting a meaningful change in clinical care.